TETRIDAR Trademark

Trademark Overview


On Thursday, June 16, 2022, a trademark application was filed for TETRIDAR with the United States Patent and Trademark Office. The USPTO has given the TETRIDAR trademark a serial number of 97462441. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Tuesday, October 31, 2023. This trademark is owned by TEVA PHARMACEUTICALS USA, Inc.. The TETRIDAR trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders; pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations
tetridar

General Information


Serial Number97462441
Word MarkTETRIDAR
Filing DateThursday, June 16, 2022
Status730 - FIRST EXTENSION - GRANTED
Status DateTuesday, October 31, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 7, 2023

Trademark Statements


Goods and ServicesPharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders; pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, January 26, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTEVA PHARMACEUTICALS USA, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Party NameTEVA PHARMACEUTICALS USA, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Trademark Events


Event DateEvent Description
Thursday, November 2, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 31, 2023SOU EXTENSION 1 GRANTED
Tuesday, October 31, 2023SOU EXTENSION 1 FILED
Tuesday, October 31, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, May 2, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, March 7, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 7, 2023PUBLISHED FOR OPPOSITION
Wednesday, February 15, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, January 27, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, January 27, 2023EXAMINER'S AMENDMENT ENTERED
Friday, January 27, 2023NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, January 27, 2023EXAMINERS AMENDMENT E-MAILED
Friday, January 27, 2023EXAMINERS AMENDMENT -WRITTEN
Wednesday, January 25, 2023ASSIGNED TO EXAMINER
Friday, July 1, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, June 20, 2022NEW APPLICATION ENTERED